Sagar Vidya Siripurapu

Statistics

Publications

Citations

H-Index

Active since

2022

Affiliations

Sagar Vidya Siripurapu is an author at University of Cologne specializing in immunotherapy, checkpoint inhibitor therapy, and non-small cell lung cancer therapy.

Publications per year

2022–2022

Publications

Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.

Tony Mok, Diego Cortinovis, Margarita Majem et al. · Journal of Clinical Oncology · 2022 · 13 citations

Medicine, Oncology, Pharmacology +17

1–1 of 1